Skip to content

Analysis of the Current Situation of Diagnosis and Treatment of Inflammatory Breast Cancer in China, Exploration of New Therapies and Development of New Targets: A Special Disease Cohort Study

Analysis of the Current Situation of Diagnosis and Treatment of Inflammatory Breast Cancer in China, Exploration of New Therapies and Development of New Targets: A Special Disease Cohort Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600127100
Enrollment
Unknown
Registered
2026-06-24
Start date
2024-10-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Treatment group:None

Sponsors

The Fourth Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age: >= 18 years old, female; 2. Previous medical diagnosis of inflammatory breast cancer, or previous medical history and physical examination showed typical clinical manifestations of inflammatory breast cancer (lesion area larger than 1/3 of the breast, disease duration less than 6 months); 3. Histopathologically confirmed as invasive breast cancer; 4. Complete pathological and imaging examination data; 5. Complete treatment strategy and follow-up data; 6. At least one measurable lesion (according to RECIST1.1 standard)

Exclusion criteria

Exclusion criteria: 1. Those whose clinical, pathological and follow-up data are incomplete; 2. Those with other malignant tumors (including second primary breast cancer), which affect the prognosis of the patients; 3. Any circumstances where the researchers consider the subjects unsuitable to participate in the study.

Design outcomes

Primary

MeasureTime frame
Pathological complete response rate;Disease free survival,DFS;Progression free survival,PFS;

Secondary

MeasureTime frame
Objective response rate,ORR;Overall survival,OS;

Countries

China

Contacts

Public ContactLiu Yunjiang

The Fourth Hospital of Hebei Medical University

lyj818326@126.com+86 137 0329 7890

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 3, 2026